Indian Pharma Companies Invite to Register 141 Medicines in Moldova

The Medicines and Medical Devices Agency of the Republic of Moldova has invited Indian pharmaceutical companies to register and export 141 pharmaceutical products for the treatment of chronic diseases such as tuberculosis, HIV, hypertension, heart disease and mental disorders.The Agency for Medicines and Medical Devices is responsible for the registration of medicines in Moldova.Medications include phenylephrine for cough-related allergies, dobutamine for cardiogenic shock and severe heart failure, arginine+sorbitol for hypertension, tenofovir disoproxil fumarate+lamivudine+dolutegravir for HIV, amoxicillin+clavulanate acid. treat bacterial infections. tenofovir alafenamide for hepatitis B infection, morphine for pain relief, rifapentine + isonic acid to treat latent tuberculosis infection, linesolidium, an antibiotic used to treat infections caused by gram-positive bacteria resistant to other antibiotics, antipsychotics haloperidol, methylphenidate to treat attention- attention deficit hyperactivity disorder (ADHD) in children and lamivudine, used among other things for the prevention and treatment of HIV/AIDS."We would like to inform the member companies that the Pharmaceutical Export Promotion Council of India (Pharmexcil) has received notification from the Ministry of Pharmaceutical Industry (DoP) that the Republic of Moldova has shared a list of 141 pharmaceutical products required by Moldova.Member companies are requested to review the list and share their willingness to deliver the drugs preferably no later than 10.11.2023, so that the Council can share the list with the DoP and the Embassy of the Republic of India in the Republic of Moldova, said Pharmexcil General Director (PO) Uday Bhaskar. "Moldova's proposal is to initially identify Indian drug exporters willing to explore this possibility. After that, the Drugs and Medical Devices Agency will be involved in fulfilling regulatory and quality certification requirements," Bhaskar added.